Shenzhen Pharmacin Co., Ltd.

Boehringer Ingelheim International Gmbh

Yunnan Institute of Materia Medica

Novartis Ag

Hlk Pharmaceuticals Co., Ltd.

Zeren Wang

Jun Xu

Richard John Varsolona

Zhi-Hui Lu

Sreeraj Macha

Wolfram Eisenreich

Long Qu

Xiao Zhang

Lijiang Wang

Guisheng Jiang

Shunqin Chen

Yulan Zhao

Meili Sun

Shirlynn Chen

Jingkun Wang

Chitra Telang

Tao Cui

Zhaoyun Zhu

Rolf-Stefan Brickl

Li Zhong

Danping Li

Shun Chen

Albert Josef Barta

Xiaohui Mei

Longwei Sun

Yanxin Zhao

Shuangxi Mei

Yong Mao

Wenqiang Sun

Bing Shi

Huilang Liu

Zeqian Li

Mayur Suryakant Dudhedia

Mei Su

Rama Ali Abu Shmeis

Jihchin Chung

Chunmei Zhao

Siddharthya Mujumdar

Steven L Krill

He Song

Tiancai Zhang

Lakshman Jayanth Parthiban

James Kowalski

Fang Yuan

Yong Liu

Min Sun

Kuanren Zhang

Yunlin Wei

Zhi Yang

Yuehai Shen

Min Su

Hongbin Liu

Minghui Wang

Leon Schultz

Nadia S Ladyzhynsky

Provided are amorphous solid dispersions comprising an active pharmaceutical ingredient and pharmaceutical compositions comprising the amorphous solid dispersions. Also described herein are methods for preparing and using such compositions. In some embodiments, an amorphous solid dispersion comprises an active pharmaceutical ingredient such as palbociclib or neratinib, one or more acids, and a high-molecular weight material.

Pharmaceutical compositions of amorphous solid dispersions and methods of preparation thereof

The present invention belongs to the pharmaceutical field, and in particular, it relates to a pharmaceutical formulation of palbociclib and a preparation method thereof. The pharmaceutical formulation comprises palbociclib, an acidic auxiliary material, and optionally a hydrophilic high-molecular material, which has better solubility and in vitro dissolution property as compared with the conventional formulation and can be used for enhancing in vivo absorption and bioavailability of palbociclib.

Pharmaceutical formulation of palbociclib and a preparation method thereof

The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material.

Preparation method therefor

Pharmaceutical composition and preparation method therefor

The application discloses five polymorph forms B, P, F, J, O of (4-((R)-((2S,5R)-4-(3-fluorobenzyl)-(2,5-dimethylpiperazine-1-yl)(3-hydroxyphenyl)methyl)phenyl)(4-methylpiperidine-1-yl)methanone dihydrochloride, preparation methods thereof and application thereof in the manufacture of a medicament for preventing or treating a mood disorder or a disease related to a &#x3b4; opioid receptor.

Polymorph of triaryldimethylpiperazine dihydrochloride and preparation method and application thereof

The present invention belongs to the pharmaceutical field, and in particular, it relates to a pharmaceutical formulation of palbociclib and a preparation method thereof. The pharmaceutical formulation comprises palbociclib, an acidic auxiliary material, and optionally a hydrophilic high-molecular weight material, which has better solubility and in vitro dissolution property as compared with the conventional formulation and can be used for enhancing in vivo absorption and bioavailability of palbociclib.

The invention belongs to the field of medicine and chemical industry, and particularly relates to multiple crystal forms of scutellarin aglycone and preparation thereof. The invention also relates to use of said crystal forms of scutellarin aglycone in the manufacture of a medicament for preventing and/or treating a cardiovascular or cerebrovascular disease, rheumatic arthritis or stroke sequelae, etc. The crystal forms of scutellarin aglycone according to the invention have good stability, and can solve the problems concerning poor oral absorption and low bioavailability of scutellarin.

Crystal forms of scutellarin aglycone and preparation thereof

Described herein are solid oral dosage forms containing Compound (1) or a pharmaceutically acceptable salt thereof (Formula 1), wherein Compound (1) is in the amorphous state. Also described are solid oral dosage forms comprising a composition of Compound (1) in the amorphous state and one or more pharmaceutically acceptable excipients. Compound (1) is a specific inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. Thus, also described herein are methods for using the described solid oral dosage forms in the treatment of HCV infection. Also described are processes for the manufacture of the solid oral dosage forms. 

Solid oral dosage formulation of HCV inhibitor in the amorphous state

This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection: 

Solid state forms of a potent HCV inhibitor

The present invention provides processes for making and forms of solid dispersions of pharmaceutical active ingredients.

Pharmaceutical formulation

Disclosed are pharmaceutical compositions of hepatitis C viral protease inhibitors, and methods of using these compositions for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. These compositions are lipid based systems and comprise the hepatitis C viral protease inhibitor together with at least one pharmaceutically acceptable amine, at least one pharmaceutically acceptable base, at least one pharmaceutically acceptable oil and optionally one or more additional ingredients.

Pharmaceutical compositions for hepatitis C viral protease inhibitors

Growing community of inventors

Southbury, CT, United States of America

Zeren Wang